Adell Harriman & Carpenter’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Adell Harriman & Carpenter’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$232K	Sell	1,464 -108	-7%	-$14.6K	0.01%	152
2026 Q1	$201K	Buy	+1,572	New	+$196K	0.01%	162
2024 Q2	–	Sell	-2,174	Closed	-$206K	–	166
2024 Q1	$206K	Sell	2,174 -949	-30%	-$88.1K	0.02%	162
2023 Q4	$279K	Sell	3,123 -584	-16%	-$43.4K	0.03%	148
2023 Q3	$271K	Buy	3,707 +60	+2%	+$4.79K	0.03%	147
2023 Q2	$302K	Sell	3,647 -510	-12%	-$42.7K	0.03%	144
2023 Q1	$317K	Sell	4,157 -160	-4%	-$13.3K	0.03%	146
2022 Q4	$358K	Sell	4,317 -3,564	-45%	-$289K	0.04%	136
2022 Q3	$625K	Sell	7,881 -530	-6%	-$44.7K	0.08%	118
2022 Q2	$625K	Buy	8,411 +990	+13%	+$74.3K	0.08%	100
2022 Q1	$667K	Sell	7,421 -2,758	-27%	-$255K	0.06%	122
2021 Q4	$1.14M	Sell	10,179 -435	-4%	-$52.5K	0.11%	107
2021 Q3	$1.33M	Sell	10,614 -2,500	-19%	-$322K	0.14%	103
2021 Q2	$1.78M	Sell	13,114 -65	-0.5%	-$8.55K	0.19%	94
2021 Q1	$1.79M	Sell	13,179 -215	-2%	-$32.2K	0.22%	88
2020 Q4	$1.89M	Sell	13,394 -555	-4%	-$71.1K	0.25%	83
2020 Q3	$1.55M	Sell	13,949 -478	-3%	-$53.6K	0.23%	78
2020 Q2	$1.62M	Sell	14,427 -805	-5%	-$79.3K	0.28%	73
2020 Q1	$1.18M	Buy	15,232 +3,035	+25%	+$269K	0.25%	78
2019 Q4	$1.16M	Buy	12,197 +2,338	+24%	+$202K	0.19%	85
2019 Q3	$752K	Buy	9,859 +2,966	+43%	+$246K	0.14%	96
2019 Q2	$605K	Buy	6,893 +1,598	+30%	+$136K	0.11%	97
2019 Q1	$479K	Buy	5,295 +107	+2%	+$9.1K	0.09%	104
2018 Q4	$372K	Buy	+5,188	New	+$418K	0.08%	121

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Adell Harriman & Carpenter's XBI Position: Q2 2026 in Review

Adell Harriman & Carpenter reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 6.9% in Q2 2026, selling an estimated $14.6K and leaving 1,464 shares worth $232K. The position accounts for 0.01% of the portfolio, ranked #152.

Adell Harriman & Carpenter first reported a position in XBI in Q4 2018 and has held it in 24 quarters since. The position peaked at $1.89M in Q4 2020. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Adell Harriman & Carpenter held 1,464 shares of State Street SPDR S&P Biotech ETF worth $232K as of Q2 2026.
Adell Harriman & Carpenter sold 108 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $14.6K.
State Street SPDR S&P Biotech ETF made up 0.01% of Adell Harriman & Carpenter's portfolio in Q2 2026, its #152 holding.
Adell Harriman & Carpenter first reported a position in State Street SPDR S&P Biotech ETF in Q4 2018 and has held it in 24 quarters since.
Adell Harriman & Carpenter's State Street SPDR S&P Biotech ETF position peaked at $1.89M in Q4 2020.
933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Adell Harriman & Carpenter's 13F filing for Q2 2026, filed 4 Aug 2026.